Navigation Links
BNCT, a new-generation radiation treatment, is effective in advanced head and neck cancer
Date:3/4/2011

Biologically targeted BNCT treatment is based on producing radiation inside a tumour using boron-10 and thermal neutrons. Boron-10 is introduced into cancer cells with the help of a special carrier substance (phenylalanine), after which the tumour is irradiated with lowenergy neutrons. The latter react with the boron to generate high-LET radiation, which may destroy the cancer cells. One to two BNCT treatment sessions may be sufficient to destroy a tumour, while keeping the impact of radiation on surrounding healthy tissue to a minimum.

A research reactor is currently used as the neutron source, but dedicated neutron accelerators being designed for BNCT.

Clinical trials to assess the efficacy and safety of BNCT in the treatment of locally recurrent head and neck cancer have been carried out at the Department of Oncology at Helsinki University Central Hospital (HUCH). Apart from palliative chemotherapy, conventional treatment was no longer considered possible for the patients treated in the BNCT trials.

A total of 30 patients referred to HUCH's Department of Oncology from hospitals around Finland took part in the trial. 76% of patients responded well to the treatment and 30% were still alive two years after treatment; although only one patient has survived 55 months. The results of the study, conducted by Professor Heikki Joensuu, have recently been published in the International Journal of Radiation Oncology, Biology, Physics.

BNCT treatment is provided by Boneca Corporation, which is based at the main campus of Helsinki University Central Hospital and is the world's only provider of radiation safetyaudited BNCT treatment. Owned by Clinical Research Institute HUCH Ltd, Sitra, Finnish Innovation Fund, and VTT Ventures Ltd., Boneca works closely with HUCH's Department of Oncology, and treatment-related decisions are taken jointly with the hospital's otolaryngology, radiation therapy and oncology specialists. Boneca is responsible for administering the treatment, which is given at a special facility adjacent to the research nuclear reactor used at the VTT Technical Research Centre of Finland.

"The positive results that we have achieved in treating head and neck tumours have convinced us of the benefits of further developing BNCT treatment and the services needed to administer it," says the Chairman of Boneca's Board of Directors, Seppo Pakkala, MD, PhD.

"As BNCT saves healthy tissue, this promises to make it a good choice as a first-line therapy for patients with large head and neck tumours, avoiding the need for extensive surgery. Additional studies will be needed, however, before BNCT can be adopted for this use. We would also like to extend the use of BNCT to treating tumours in other anatomical areas for which there are no forms of treatment currently available."

BNCT treatment has been given to over 200 patients to date, the majority of whom had recurred head and neck cancer or malignant brain tumour. Approximately 6% of patients have come from abroad as a result of international interest in BNCT.

"We have sufficient capacity to treat more patients and are very interested in collaborating with hospitals outside Finland that would like to offer the option of BNCT treatment for their patients," says Boneca's CEO, Markku Pohjola.


'/>"/>

Contact: Dr. Seppo Pakkala
seppo.pakkala@hus.fi
358-505-596-549
University of Helsinki
Source:Eurekalert

Related medicine news :

1. Many Dialysis Patients at Risk for High Radiation Exposure
2. ACR commission and committee chairs and former board chair to present at NIH Radiation Dose Summit
3. Protective strategy shields primate ovaries from radiation-therapy-induced damage
4. Smoking during radiation treatments reduces chance of overall survival
5. Breast cancer screening with MRI benefits women with radiation therapy history
6. New initiative provides materials to help lower radiation dose in pediatric fluoroscopic procedures
7. Risk of cancer increases with exposure to low-dose radiation
8. Princess Margaret Hospital researchers identify a key enzyme that affects radiation response
9. Practical Radiation Oncology publishes first issue
10. HIV-positive head and neck cancer patients benefit from radiation therapy
11. Breast Cancer Radiation Before 1984 Tied to Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel ... CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. ... brings extensive financial and operational leadership experience to Advanced Inc. He began his career ...
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Yisrayl Hawkins, at ... into how this current generation fits into Bible Prophecy. Yisrayl says this generation, known ... pointing to this conclusion, showing how the details line up exactly with Bible Prophecy ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... GARDENS, N.Y. , Dec. 2, 2016  LifeVac, ... will be included in the Emergency Response Training and ... are very excited to have LifeVac become part of ... Lih , Founder and CEO of LifeVac. "Having an ... LifeVac safely and effectively will help leverage our efforts ...
(Date:12/2/2016)... Dec. 2, 2016  PipelineRx, a leading medication management ... offering demonstrations of its SaaS-based telepharmacy platform, ... Pharmacists 2016 Midyear Clinical Meeting and Exhibition, December ... With nearly 300 hospital clients nationally, the Company ... designed to dramatically improve pharmacy operations, enhance patient ...
(Date:12/2/2016)...  Maxor National Pharmacy Services, LLC ("Maxor"), today announced that ... The combination of Texas -based Maxor Specialty ... bring together both company,s clinical expertise and high-touch patient service ... specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: